By the Top Tier Newswire AI Desk · November 17, 2026 at 10:32 AM ET · reviewed against 4 wire stories
ERASCA INC (ERAS) is down -6.49% in the latest session. Our newswire has captured 4 stories on ERAS across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Erasca (ERAS) shares fell 6.49% to $14.13 on Monday. The primary driver for the decline appears to be a pullback from recent highs, despite fresh initiation coverage and an upcoming investor event.
What Happened
Leerink initiated coverage on Erasca with an Outperform rating, a move that typically signals institutional confidence in the company's clinical trajectory. Concurrently, the company announced it will host a virtual investor event on November 20, 2026, to highlight clinical momentum across its RAS-targeting franchise. This event follows the release of third-quarter 2026 financial results and business updates. The stock had recently printed a fresh 52-week high, setting the stage for potential profit-taking. Additionally, background context includes the start of a combination clinical trial with Tango Therapeutics and ongoing patent infringement allegations regarding ERAS-0015.
What The Data Shows
The intraday session showed significant volatility, opening at $15.15 and hitting a session high of $15.84 at 9:05 AM ET. The stock then slid to a session low of $14.13 at 10:30 AM ET, closing near that low at $14.19. Volume was 1.6 million shares, which is 0.3 times the three-month daily average, indicating lighter participation than usual. Fundamentals show a market cap of $5.5 billion with the company remaining unprofitable, posting a trailing twelve-month EPS of -0.99. The stock has a beta of 0.65 and a 52-week range of $2.50 to $24.28. Over the last eight sessions, the stock moved down 5.0% from $14.78 to $14.04. The 52-week tape recorded one fresh high and 20 fresh lows on November 17, 2026.
What To Watch
Investors should monitor the virtual investor event scheduled for November 20, 2026, where Erasca plans to detail its clinical progress. The upcoming date provides a near-term catalyst for the stock, which has seen improving sentiment trends over the last seven days.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ERAS · Nov 17 session (5-min) · -7.41% vs prior close · updated 8:46 PM ETAI sentiment, last 36h · averaged over 4 stories · 61/100 bullish
The headlines behind the move
Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoThe FlyBULLISH 64Analyst
Leerink bullish on Erasca, initiates with an Outperform
3d agoThe FlyBULLISH 63Analyst
Erasca initiated with an Outperform at Leerink
4d agoGlobeNewswireBULLISH 58Product/PR
Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
4d agoStockTitanBULLISH 58Product/PR
Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →